Delivering Speed and Results through Advanced Technology and Collaboration

Summary: Enzymes can be challenging to express and scale up to become biologic therapies.  In order to develop their optimized tissue plasmigen activator (tPA) to treat patients with hemorrhagic stroke, Op2Lysis came to Catalent Biologics to develop a cell line expressing their optimized tPA enzyme.  By leveraging GPEx® cell line development technology and the expertise of the Madison, Wisconsin team, Op2Lysis was able to work with Catalent Biologics to quickly develop highly expressing clonal cell lines that highly expressed the enzyme.